文献速递肝病消化内镜

替诺福韦或恩替卡韦治疗11年的HBV代偿期肝硬化患者长期内镜监测

Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years.
PubMed 文献 · Aliment Pharmacol Ther · 2023-03-28

本研究为长期队列研究,纳入186例接受替诺福韦或恩替卡韦治疗的HBV单感染代偿期肝硬化白种人患者,随访11年并行666次内镜检查。结果显示食管或胃静脉曲张新发或进展的11年累积概率为5.1%(95% CI 3-10%),无患者出血;基线无食管静脉曲张者11年概率为4.5%,基线低风险静脉曲张者进展与消退概率分别为9.3%和58%。

要点

  • 长期有效替诺福韦或恩替卡韦治疗下,11年食管或胃静脉曲张新发或进展风险低。
  • 基线无食管静脉曲张者11年累积概率为4.5%,且均出现在治疗前6年内。
  • 基线低风险静脉曲张者11年进展概率9.3%,消退概率58%。

核心结论

  • 在长期有效替诺福韦或恩替卡韦治疗的代偿期肝硬化患者中,11年发生或进展食管静脉曲张的风险可忽略不计,对基线无食管静脉曲张患者的现行内镜监测建议提出挑战。

研究设计与样本

  • 长期队列研究,纳入186例自替诺福韦或恩替卡韦开始治疗起入组的HBV单感染代偿期肝硬化白种人患者,按Baveno建议行上消化道内镜检查。

主要发现

  • 在11年抗病毒治疗及666次内镜检查期间,9例患者出现食管或胃静脉曲张新发或进展,11年累积概率为5.1%(95% CI 3-10%),无患者出血。
  • 基线无食管静脉曲张的161例患者中,11年概率为4.5%,所有静脉曲张均在治疗前6年内出现。
  • 基线低风险静脉曲张的25例患者中,11年进展概率为9.3%,消退概率为58%。
  • 多因素分析显示仅基线血小板计数与低风险静脉曲张发生相关(HR 0.96,p=0.028)。
  • 血小板≤90,000/mmc(AUROC 0.70)预测低风险静脉曲张发生的特异性为98.1%、敏感性为42.9%、阳性预测值为50%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Long-term administration of TDF/ETV in patients with HBV-related compensated cirrhosis reduces HCC and decompensation events but the effect of this regimen on development/regression of oesophageal varices (EV) is currently unknown. AIM: To assess the risk of EV development/progression in this population. METHODS: A total of 186 Caucasian HBV-monoinfected compensated cirrhotics were enrolled in a long-term cohort study from TDF/ETV introduction. Upper GI endoscopies were performed according to Baveno recommendations. Primary endpoint was development/progression of oesophageal/gastric varices over time. RESULTS: At TDF/ETV start, median age was 61 years, 80% males, 60% HBV-DNA undetectable, 63% NUCs previously exposed, 73% normal ALT, 40% platelets <150,000/mmc and 25 (13%) with low-risk varices (LRV). During 11 years of antiviral therapy and 666 endoscopies performed, 9 patients either developed or had a progression of oesophageal or gastric varices with an 11-year cumulative probability of 5.1% (95% CI 3-10%); no patient bled. Out of 161 patients without EV at baseline, the 11-year probably was 4.5% with all varices developing within the first six years of treatment. In 25 patients with LRV at baseline, the 11-year probability of progression or regression was 9.3% and 58%, respectively. Only baseline platelet count (HR 0.96, p = 0.028) was associated with LRV development at multivariate analysis: platelet ≤90,000/mmc (AUROC 0.70) had 98.1% specificity, 42.9% sensitivity, 50% PPV for LRV onset. CONCLUSIONS: In compensated cirrhotic patients under long-term effective TDF/ETV treatment, the 11-year risk of developing/progressing EV is negligible, thus challenging the current endoscopic surveillance recommendations in patients without EV at baseline.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Farina E, Loglio A, Tosetti G, et al. Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years. Aliment Pharmacol Ther. 2023. PMID: 36978230. doi:10.1111/apt.17463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。